Skip to main content
. Author manuscript; available in PMC: 2020 Feb 13.
Published in final edited form as: Oncogene. 2019 Aug 13;38(44):7017–7034. doi: 10.1038/s41388-019-0923-2

Figure 7. LSD1 is a suppressor of human luminal breast cancer and metastasis.

Figure 7.

(a) A proposed model of LSD1 in maintaining luminal MEC differentiation (e.g., luminal epithelial cell adhesion gene expression) and in inhibiting their invasion, migration and possibly also metastasis.

(b) OncoPrint showing cases with LSD1 (KDM1A) deep deletion or mutation from the TCGA breast cancer cohort, their overall survival status and ER status, by using the cbioportal online tool.

(c-h) Kaplan-Meier curves showing lower levels of LSD1 (c-e) and higher levels of TRIM37 (f-h) are associated with worse any event (AE)-free survival in patients with luminal A breast cancers in three different cohorts [c, f: Hu’s SSP (Single Sample Predictor); d, g: Sorlie’s SSP; e, h: PAM50 SSP], based on bc-GenExMiner online tool.